Fresenius Kabi AG - Company Profile
Powered by 
All the sales intelligence you need on Fresenius Kabi AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fresenius Kabi AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fresenius Kabi AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fresenius Kabi AG (Fresenius Kabi), a subsidiary of Fresenius SE & Co KGaA is a healthcare company. It specializes in life-saving medicines and medical technologies, including intravenous (IV) drugs, medical nutrition, infusion technologies, cell therapies, blood collection, and biopharmaceuticals. Its product portfolio covers therapeutic areas such as oncology, anti-infectives, anesthesia, analgesia, and critical care. The company provides a wide range of injectable medications, pain management solutions, and critical care treatments. Fresenius Kabi also offers enteral and parenteral nutrition through its Fresubin range and advanced medical technologies like infusion pumps and apheresis devices. Its biopharmaceuticals focus on autoimmune diseases and oncology, supported by the KabiCare patient assistance program. Fresenius Kabi is headquartered in Bad Homburg, Germany.
Headquarters
Germany
Address
Else-Kroner-Strasse 1, Bad Homburg, Hessen, 61352
Website
www.fresenius-kabi.com
Telephone
49 6172 6860
No of Employees
40,000
Industry
Medical Equipment
Revenue (2024)
$9.1B
Fresenius Kabi AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Intravenous (IV) Fluids: | Contract Development and Manufacturing (CDMO) Services | Fresubin |
| Electrolyte solutions | KabiCare | |
| Colloids | Bomyntra | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In December, the company announced the launch of its denosumab biosimilars, Conexxence (denosumab) and Bomyntra (denosumab), in Europe. |
| 2025 | New Products/Services | In November, the company launched Dalbavancin for Injection. |
| 2025 | Divestiture | In September, the company sold Calea Ltd. to Capital Health Partners Inc. |
Competitor Comparison
| Key Parameters | Fresenius Kabi AG | Cardinal Health Inc | Abbott Laboratories | Sandoz Inc | Elekta AB |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United States of America | United States of America | Sweden |
| City | Bad Homburg | Dublin | Abbott Park | Princeton | Stockholm |
| State/Province | Hessen | Ohio | Illinois | New Jersey | - |
| No. of Employees | 40,000 | 57,700 | 115,000 | - | 4,536 |
| Entity Type | Private | Public | Public | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pierluigi Antonelli | Chief Executive Officer | Senior Management | 2023 | 62 |
| Andreas Duenkel | Chief Financial Officer | Senior Management | 2022 | - |
| Tanja Bender | Chief Human Resources Officer | Senior Management | 2025 | - |
| Christian Hauer | President - MedTech | Senior Management | 2022 | - |
| Marc-Alexander Mahl | President - Pharma, Nutrition and Sustainability | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer